reports
Artisan Partners Asset Management Inc. Reports February 2026 Assets Un...
Artisan Partners Asset Management Inc. Reports February 2026 Assets Under Management MILWAUKEE, March 10, 2026 (GLOBE NEWSWIRE) -- Artisan Partners Asset Management Inc. (NYSE: APAM) today reported that its preliminary assets under management ("AUM") as of February 28, 2026 totaled $188.5 billion. Artisan Funds and Artisan Global Funds accounted for $92.4 billion of total firm AUM, while separate accounts and other AUM1 accounted for $96.1 billion. PRELIMINARY ASSETS UNDER MANAGEMENT BY STRATEGY2 As of February 28, 2026 - ($ Millions) Growth Team Global Opportunities$15,690 Global D...
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Marke...
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore’s participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat...
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results a...
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a...
Lifecore Biomedical to Report Financial Results for the Fourth Quarter...
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026 Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and transition period ended December 31, 2025, on Monday, March 16, 2026, before the market opens. At 8:30 a.m. Eastern Time t...
Hyperion DeFi Announces Private Lending Pool Built by HyperLend
Hyperion DeFi Announces Private Lending Pool Built by HyperLend Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Opportunities in Institutional Credit LAGUNA HILLS, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today announced that it has engaged with the HyperLend protocol (“HyperLend”) to create a permissioned lending pool native to the HyperEVM. Through this pool, Hyperion DeFi will utilize its HYPE Liquid Staking Token (LST), HiHYPE, as collateral to access credit on-...
Rhythm Pharmaceuticals Inc: 1 director
A director at Rhythm Pharmaceuticals Inc sold/sold after exercising options 5,614 shares at 89.560USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovat...
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clini...
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s D...
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Poten...
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3...
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focus...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fi...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Finan...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO ...
BBSI Reports Strong Fourth Quarter and Full Year 2025 Financial Result...
BBSI Reports Strong Fourth Quarter and Full Year 2025 Financial Results - Fourth Quarter Revenues up 5% to $321.1 Million With Net Income of $16.4 Million, or $0.64 per Diluted Share - VANCOUVER, Wash., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Year-ago Quarter Revenues up 5% to $321.1 million.Gross billings up 6% to $2.40 billion.Average w...
American Assets Trust Inc: 1 director
A director at American Assets Trust Inc bought 82,386 shares at 19.417USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results...
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours afte...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: TD Cowen Annual Healthcare ConferenceFireside Chat March 3, 2026, at 9:50 am ET Leerink Partners Global Healthcare ConferenceFireside ChatMarch 10, 2026, at 4:20 pm ET Live webcasts and replays, when available, can ...
Avalo Therapeutics Announces Inducement Grants to New Employees Under ...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 82,000 shares of common stock (the “Options”) as inducem...
Esperion to Participate in The 2026 Citizens Life Sciences Conference
Esperion to Participate in The 2026 Citizens Life Sciences Conference ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. About Esperion TherapeuticsEsperion Th...
AMERANT BANK APPOINTS TONY EELMAN AS EXECUTIVE VICE PRESIDENT AND CHIE...
AMERANT BANK APPOINTS TONY EELMAN AS EXECUTIVE VICE PRESIDENT AND CHIEF PRODUCT OFFICER Coral Gables, FL, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Amerant Bank, Florida’s bank of choice with a growing presence across South Florida, is pleased to announce the appointment of Tony Eelman as EVP, Chief Product Officer. A senior financial services and mortgage-banking executive will now lead enterprise product strategy across the bank’s financial services and program-based lending platforms. In his new role, Eelman will focus on aligning product design, leveraging on technology, and progressing o...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Fin...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. To access the live conference call, part...
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Mar...
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expir...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.